NCT03472235

Brief Summary

Melasma is an acquired disorder of hyperpigmentation characterised by blotchy, light-to-dark brown macules distributed symmetrically on the sun-exposed parts of the body. Although many factors have been proposed to have a role in pathogenesis, the exact ethology is yet to be understood. The most commonly identifiable risk factors include ultraviolet radiation, genetic predisposition, pregnancy, oral contraceptives, thyroid disease and drugs like antiepileptic. The excessive pigmentation has been attributed to both melanocytosis (increased number of melanocytes) as well as melano genesis (excess production of melanin) as confirmed in a histopathological study on Asian patients.\] Furthermore, a vascular component has also been proposed to play a role in the pathogenesis of melisma. Kim et al. have found that lesion melasma skin had greater expression of the vascular endothelial growth factor in keratinocytes compared to nearby nonlesional skin.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2018

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 7, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

March 21, 2018

Completed
15 days until next milestone

Study Start

First participant enrolled

April 5, 2018

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 5, 2019

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

April 5, 2020

Completed
Last Updated

March 21, 2018

Status Verified

February 1, 2018

Enrollment Period

1 year

First QC Date

February 7, 2018

Last Update Submit

March 20, 2018

Conditions

Outcome Measures

Primary Outcomes (2)

  • Scoring of the patients according to modified melasma are abd severity index [mMASI] Scoring before and After last session will be done by 1 month

    Efficacy of the treatment =(mMASIscorebefor -mMASIscoreafter)/mMASIscore before x100. Clinical efficacy was categorized into : Excellent response: if morethan 75%fall in \[mMASI\] score. Very good response:if 50-75%fall in \]mMASI\[score . Good respone: if 25-50%fall in \]mMASI\[score. Poor response: if less25%fall in mMASIscore. No response: when there was no change in \[mMASI\] score at the end of the therapy. Efficacy of the treatment =(mMASIscorebefor -mMASIscoreafter)/mMASIscore before x100. Clinical efficacy was categorized into : Excellent response: if morethan 75%fall in \[mMASI\] score. Very goodresponse:if 50-75%fall in \]mMASI\[score . Good respone: if 25-50%fall in \]mMASI\[score. Poor response: if less25%fall in mMASIscore. No response: when there was no change in \[mMASI\] score at the end of the therapy.

    1 month after last session

  • [mMASI] Scoring before and After last session will be done by 3 months

    before x100. Clinical efficacy was categorized into : Excellent response: if morethan 75%fall in \[mMASI\] score. Very good response:if 50-75%fall in \]mMASI\[score . Good respone: if 25-50%fall in \]mMASI\[score. Poor response: if less25%fall in mMASIscore. No response: when there was no change in \[mMASI\] score at the end of the therapy. Efficacy of the treatment =(mMASIscorebefor -mMASIscoreafter)/mMASIscore before x100. Clinical efficacy was categorized into : Excellent response: if morethan 75%fall in \[mMASI\] score. Very goodresponse:if 50-75%fall in \]mMASI\[score . Good respone: if 25-50%fall in \]mMASI\[score. Poor response: if less25%fall in mMASIscore. No response: when there was no c

    3 months after last session

Study Arms (2)

A

ACTIVE COMPARATOR

include 20 patients will be treated with TCA25% +microneedle 8 sessions for TCA 25 peel and 4 sessions for microneedle (derma pen).

Device: Microneedle

B

ACTIVE COMPARATOR

include 20 patient will be treated with TCA 25% only ( 8 sessions)

Device: Microneedle

Interventions

TCA peeling session: Facial skin will be cleansed with tap water and degreased by rubbing with an alcohol sponge . Then TCA 25% will be applied to the whole face by cotton tipped applicator or gauze pad. The entire face will be treated until complete frosting occur. The patients will be instructed to wash their faces to decrease the burning sensation. Combined session: starts with microneedle using microneedle device (Derma pen) The skin of each patient is cleaned with anti septic solution and anesthetic cream may be applied to lessen discomfort. (Dermapen) will be applied on the lesional skin in four direction, vertical, horizontal and in the two diagonal until pin point bleeding occur which will be gently massaged . After 10 minutes TCA peeling will be applied TCA peeling will be done for 8 session with 2 weeks interval between each session. Microneedle will be done for 4session with 4 weeks interval between each session.

AB

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Both sex will be included Age range from 18- 50 yrs.' old Patients with realistic expectations.

You may not qualify if:

  • patients taking oral contraceptive pills. patients with history of polycystic ovary. pregnant and lactating females. patients with active infection. patients on isotretinoin. patients with history of keloids,or hypertrophic scars.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol. 2011 Oct;65(4):699-714. doi: 10.1016/j.jaad.2011.06.001.

    PMID: 21920242BACKGROUND

MeSH Terms

Conditions

Melanosis

Condition Hierarchy (Ancestors)

HyperpigmentationPigmentation DisordersSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: TCA peeling session: Facial skin will be cleansed with tap water and degreased by rubbing with an alcohol sponge . Then TCA 25% will be applied to the whole face by cotton tipped applicator or gauze pad. The entire face will be treated until complete frosting occur. The patients will be instructed to wash their faces to decrease the burning sensation. Combined session: starts with microneedling using microneedling device (Dermapen) The skin of each patient is cleaned with anti septic solution and anesthetic cream may be applied to lessen discomfort. (Dermapen) will be applied on the lesional skin in four direction, vertical, horizontal and in the two diagonal until pin point bleeding occur which will be gently massaged . After 10 minutes TCA peeling will be applied TCA peeling will be done for 8 session with 2 weeks interval between each session. Microneedling will be done for 4session with 4 weeks interval between each session.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

February 7, 2018

First Posted

March 21, 2018

Study Start

April 5, 2018

Primary Completion

April 5, 2019

Study Completion

April 5, 2020

Last Updated

March 21, 2018

Record last verified: 2018-02

Data Sharing

IPD Sharing
Will not share